Oxytocin Administration During Cesarean Section

Oxytocin Administration During Cesarean Section Before Versus After Fetal Delivery Randomized Clinical Trial

Status

Completed

Phases

Phase 4

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT03344302

Enrollment

200

Registered

2017-11-17

Start date

2016-10-31

Completion date

2017-09-30

Last updated

2018-04-23

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Postpartum Hemorrhage

Brief summary

Cesarean delivery is defined as fetal birth through incisions in the abdominal wall and the uterine wall. This definition does not include removal of the fetus from the abdominal cavity in the case of uterine rupture or in the case of an abdominal pregnancy The guidelines of the Royal College of Obstetricians and Gynaecologists on caesarean section recommend a slow intravenous bolus dose of 5 IU of oxytocin after delivery of the infant. Intravenous oxytocin has a short half life (4-10 minutes); therefore the potential advantage of an oxytocin infusion at caesarean section is in maintaining uterine contractility throughout the surgical procedure and immediate postpartum period, when most primary haemorrhage occurs

Interventions

DRUGOxytocin

intravenous infusion of oxytocin 30 units over 5 minutes diluted into 500 mL of normal 0.9% sodium chloride

Study design

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

PREVENTION

Masking

SINGLE (Subject)

Eligibility

Sex/Gender

FEMALE

Age

20 Years to 40 Years

Healthy volunteers

Inclusion criteria

* Primigravida or multigravida * Term (37 - 42 weeks), * Singleton pregnancies * Booked for elective caesarean section. * Accepting to participate in the study.

Exclusion criteria

* • Medical disorders involving the heart, liver, kidney or brain. * Diabetes mellitus and hypertension. * Blood disorders (e.g. coagulopathies, thrombocytopenia) * Patients requiring blood transfusion due to anemia. * Risk factors for uterine atony e.g. macrosomia, polyhydramnios and multiple pregnancy. * Previous 2 or more cesarean section * Placenta previa or placental abruption * Previous major obstetric haemorrhage (\>1000 ml) in previous deliveries. * Known fibroid or adenomyosis. * Women who received anticoagulant therapy. * Severe preeclampsis. * Uterine anomalies.

Design outcomes

Primary

Measure	Time frame	Description
rate of blood loss	4 hours	collection of the blood in the drape below the patient

Countries

Egypt

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026